Skip to content

Allen & Overy advises Vivere Lifesciences on its proposed listing on the Hong Kong Stock Exchange

Related people
Lee Lina
Lina Lee

Partner

Hong Kong

View profile →

Ryan Tou

Of Counsel

Hong Kong

View profile →

Stathopoulos Alexander
Alexander Stathopoulos

Partner

Singapore

View profile →

24 February 2022

Allen & Overy is advising the issuer, Vivere Lifesciences Acquisition Corp. (Vivere Lifesciences) on its proposed listing on the Hong Kong Stock Exchange (HKEX).

Vivere Lifesciences is a special purpose acquisition company (SPAC) backed by VMS Asset Management and I-Mab (Nasdaq: IMAB) as its key promoters.

The Company intends to focus on identifying de-SPAC targets in the healthcare industry in China or other global opportunities with a significant China angle.

Partner Lina Lee commented, “We were delighted to assist Vivere Lifesciences on this transaction under the new SPAC listing regime in Hong Kong. The HKEX’s rules, which went into effect in January 2022 seeks to achieve a balanced regime that safeguard investors’ interests but at the same time meet the capital raising needs of the market. We are likely to continue to see significant interest from sponsors and institutional investors in SPACs and that bodes well for the Hong Kong market.”

Allen & Overy is actively advising a number of SPACs across the Asia Pacific region on their listings and business combination transactions.

The team advising on the transaction was led by the Head of Allen & Overy’s Hong Kong corporate team, partner Lina Lee, with support from Ryan Tou (Counsel) and Michelle Tsang (Associate), with US securities support from Alex Stathopoulos (Partner).